Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A RAndomised Placebo Controlled Trial - to Explore the Efficacy and Mechanism of Action of Tezepelumab in Eosinophilic Granulomatosis With Polyangiitis

NCT06230354 is registered in ClinicalTrials.gov with Imperial College London as lead sponsor.

NCT NCT06230354
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06230354 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A RAndomised Placebo Controlled Trial - to Explore the Efficacy and Mechanism of Action of Tezepelumab in Eosinophilic Granulomatosis With Polyangiitis
Lead sponsor
Imperial College London
Phase
Phase 2
Overall status
Active, not recruiting
Start date
May 15, 2024
Completion date
September 30, 2026
Enrollment
42 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

egpa - eosinophilic granulomatosis with polyangiitis